Botulinum antibodies in dystonic patients treated with type A botulinum toxin

Abstract

We measured serum antibodies to botulinum toxin (ABT) in 96 patients with focal dystonia who had been treated with type A botulinum toxin. The frequency of detectable ABT was 3% (three patients). Patients with ABT had received more than 50 ng of botulinum toxin, and the shortest time between two injections was significantly less than in patients without ABT. The clinical evolution of the three patients was heterogeneous: one had decreased effectiveness with repeated injections, another had persistent improvement, and the third never responded to toxin injections.

Botulinum Toxin and Other New Approaches to Migraine Therapy

“…Using an older formulation, it was estimated to occur in at least 5%-10% of patients with cervical dystonia (11). Factors that increase the risk for antibody formation include higher doses and short intervals between doses (12)(13)(14). With the new formulation and the relatively low doses used in migraine treatment (see below), this complication is unlikely to occur.…”

Multiple Pocket Recognition of SNAP25 by Botulinum Neurotoxin Serotype E

“…Thus, there is a need to develop more efficient vaccines and therapies against botulism. In addition, because of their specific recognition and cleavage of SNARE proteins, BoNTs are widely utilized as therapeutic agents to treat various neurological disorders of dystonia and spinal spasticity, including blepharospasm, torticollis, and spasmodicus (12) and as well as being utilized as tools for investigating intracellular vesicular trafficking and the mechanism of membrane fusion (13)(14)(15). Understanding the substrate specificity of BoNT will provide insight into the development of therapies against BoNT intoxication and the modification of BoNT to optimize therapeutic potential and extend our tools to study intracellular vesicular trafficking and the mechanisms of membrane fusion.…”

Lower Relapse Rate of Botulinum Toxin A Therapy for Axillary Hyperhidrosis by Dose Increase

“…Repeated application may induce specific antibodies that can reduce the efficacy of this treatment by immunoresistance. 13,14 In the present study, we investigated the efficacy and safety of high-dose botulinum toxin A in patients with palmar and axillary hyperhidrosis. We also wanted to find out if a higher initial dose would prolong its anhidrotic effect.…”